Cocrystal Pharma Doses First Subjects In Phase 1 Study of CDI-988 For Pandemic Norovirus and Coronavirus
Portfolio Pulse from Benzinga Newsdesk
Cocrystal Pharma has begun dosing subjects in a Phase 1 study of CDI-988, a potential treatment for pandemic Norovirus and Coronavirus.
September 28, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cocrystal Pharma's initiation of Phase 1 study for CDI-988 could potentially boost its stock as it represents progress in the company's product pipeline.
The initiation of a Phase 1 study is a significant milestone in drug development. This news indicates progress in Cocrystal Pharma's product pipeline, which could positively impact investor sentiment and potentially lead to a rise in the company's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100